No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GH240719P25000
- 0.05
- 0.000.00%
15min DelayClose Jul 17 14:48 ET
0.05High0.05Low
0.05Open0.05Pre Close4 Volume393 Open Interest25.00Strike Price20.00Turnover199.30%IV23.35%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0269Delta0.0134Gamma651.00Leverage Ratio-0.0474Theta0.0000Rho-17.52Eff Leverage0.0014Vega
Intraday
- 5D
- Daily
News
Express News | Guardant Health Inc : Bernstein Raises Target Price to $37 From $33
Assessing Guardant Health: Insights From 7 Financial Analysts
In the latest quarter, 7 analysts provided ratings for Guardant Health (NASDAQ:GH), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing
Express News | Goldman Sachs Maintains Buy on Guardant Health, Raises Price Target to $32
Express News | Guardant Health Inc : TD Cowen Raises Target Price to $41 From $37
Express News | Guardant Health Inc : TD Cowen Raises Target Price to $42 From $37
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we
Comments
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? 1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake(SNOW.US$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Read more